These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19002577)

  • 1. Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha.
    Lam L; Hu X; Aktary Z; Andrews DW; Pasdar M
    Breast Cancer Res Treat; 2009 Dec; 118(3):605-21. PubMed ID: 19002577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780.
    Chan TW; Pollak M; Huynh H
    Clin Cancer Res; 2001 Aug; 7(8):2545-54. PubMed ID: 11489838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiestrogen ICI 182,780 decreases proliferation of insulin-like growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling.
    Varma H; Conrad SE
    Cancer Res; 2002 Jul; 62(14):3985-91. PubMed ID: 12124331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
    J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes.
    Zhang Y; Moerkens M; Ramaiahgari S; de Bont H; Price L; Meerman J; van de Water B
    Breast Cancer Res; 2011 May; 13(3):R52. PubMed ID: 21595894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor binding protein-4 and -5 modulate ligand-dependent estrogen receptor-α activation in breast cancer cells in an IGF-independent manner.
    Hermani A; Shukla A; Medunjanin S; Werner H; Mayer D
    Cell Signal; 2013 Jun; 25(6):1395-402. PubMed ID: 23499909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor alpha (ERalpha) and insulin-like growth factor I receptor (IGF-IR) cross-talk in the gonadotropic alphaT3-1 cell line.
    Eertmans F; Dhooge W; De Wever O; Bracke M; Comhaire F; Kaufman JM
    J Cell Physiol; 2007 Sep; 212(3):583-90. PubMed ID: 17458895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.
    Frogne T; Jepsen JS; Larsen SS; Fog CK; Brockdorff BL; Lykkesfeldt AE
    Endocr Relat Cancer; 2005 Sep; 12(3):599-614. PubMed ID: 16172194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
    Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
    Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
    Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
    Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells.
    Lee YR; Park J; Yu HN; Kim JS; Youn HJ; Jung SH
    Biochem Biophys Res Commun; 2005 Nov; 336(4):1221-6. PubMed ID: 16169518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
    Brockdorff BL; Heiberg I; Lykkesfeldt AE
    Endocr Relat Cancer; 2003 Dec; 10(4):579-90. PubMed ID: 14713268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance.
    Louie MC; McClellan A; Siewit C; Kawabata L
    Mol Cancer Res; 2010 Mar; 8(3):343-52. PubMed ID: 20215421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells.
    Horner-Glister E; Maleki-Dizaji M; Guerin CJ; Johnson SM; Styles J; White IN
    J Mol Endocrinol; 2005 Dec; 35(3):421-32. PubMed ID: 16326830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hexachlorobenzene induces cell proliferation and IGF-I signaling pathway in an estrogen receptor alpha-dependent manner in MCF-7 breast cancer cell line.
    García MA; Peña D; Alvarez L; Cocca C; Pontillo C; Bergoc R; de Pisarev DK; Randi A
    Toxicol Lett; 2010 Feb; 192(2):195-205. PubMed ID: 19879930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a human breast cancer cell line, MCF-7/RU58R-1, resistant to the pure antiestrogen RU 58,668.
    Fog CK; Christensen IJ; Lykkesfeldt AE
    Breast Cancer Res Treat; 2005 May; 91(2):133-44. PubMed ID: 15868441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines.
    Treeck O; Haldar C; Ortmann O
    Oncol Rep; 2006 Jan; 15(1):231-5. PubMed ID: 16328061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-genomic actions of estradiol and 4-OH-tamoxifen on murine breast cancer cells.
    Raffo D; Pontiggia O; Bal de Kier Joffé E; Simian M
    Oncol Rep; 2015 Jan; 33(1):439-47. PubMed ID: 25338647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.